CGON vs. FUSN, DNA, NVAX, INBX, BEAM, SANA, ADMA, NMRA, KYMR, and TARS
Should you be buying CG Oncology stock or one of its competitors? The main competitors of CG Oncology include Fusion Pharmaceuticals (FUSN), Ginkgo Bioworks (DNA), Novavax (NVAX), Inhibrx (INBX), Beam Therapeutics (BEAM), Sana Biotechnology (SANA), ADMA Biologics (ADMA), Neumora Therapeutics (NMRA), Kymera Therapeutics (KYMR), and Tarsus Pharmaceuticals (TARS). These companies are all part of the "biological products, except diagnostic" industry.
Fusion Pharmaceuticals (NASDAQ:FUSN) and CG Oncology (NASDAQ:CGON) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, profitability, dividends, media sentiment, analyst recommendations, community ranking, valuation, risk and institutional ownership.
CG Oncology has a net margin of 0.00% compared to CG Oncology's net margin of -4,136.55%. Fusion Pharmaceuticals' return on equity of 0.00% beat CG Oncology's return on equity.
Fusion Pharmaceuticals received 33 more outperform votes than CG Oncology when rated by MarketBeat users. However, 80.00% of users gave CG Oncology an outperform vote while only 64.06% of users gave Fusion Pharmaceuticals an outperform vote.
72.9% of Fusion Pharmaceuticals shares are held by institutional investors. Comparatively, 26.6% of CG Oncology shares are held by institutional investors. 7.8% of Fusion Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
In the previous week, CG Oncology had 9 more articles in the media than Fusion Pharmaceuticals. MarketBeat recorded 11 mentions for CG Oncology and 2 mentions for Fusion Pharmaceuticals. CG Oncology's average media sentiment score of 0.65 beat Fusion Pharmaceuticals' score of 0.25 indicating that Fusion Pharmaceuticals is being referred to more favorably in the media.
Fusion Pharmaceuticals currently has a consensus price target of $20.25, suggesting a potential downside of 5.68%. CG Oncology has a consensus price target of $63.75, suggesting a potential upside of 105.84%. Given Fusion Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe CG Oncology is more favorable than Fusion Pharmaceuticals.
CG Oncology has lower revenue, but higher earnings than Fusion Pharmaceuticals.
Summary
CG Oncology beats Fusion Pharmaceuticals on 10 of the 15 factors compared between the two stocks.
Get CG Oncology News Delivered to You Automatically
Sign up to receive the latest news and ratings for CGON and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CGON and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
CG Oncology Competitors List
Related Companies and Tools
